We are live on ! Find out more
GTC

Ghost Tree Capital Portfolio holdings

AUM $331M
1-Year Est. Return 70.11%
This Fund
S&P 500
This Quarter Est. Return
+26.87%
1 Year Est. Return
+70.11%
3 Year Est. Return
+265.05%
5 Year Est. Return
+3,034.98%
10 Year Est. Return
+22,104.75%
AUM
$494M
AUM Growth
+$67.8M
Cap. Flow
-$71M
Cap. Flow %
-14.37%
Top 10 Hldgs %
52.79%
Holding
80
New
31
Increased
8
Reduced
10
Closed
27

Top Buys

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$15.7M
2
IOVA icon
Iovance Biotherapeutics
IOVA
+$15.1M
3
ECYT
Endocyte, Inc. Common Stock
ECYT
+$12.1M
4
FOLD
Amicus Therapeutics
FOLD
+$11.4M
5
GYRE icon
Gyre Therapeutics
GYRE
+$11.2M

Top Sells

Rank Stock Value
1
ESPR
Esperion Therapeutics
ESPR
+$15.1M
2
ALXN
Alexion Pharmaceuticals
ALXN
+$13.8M
3
GBT
Global Blood Therapeutics, Inc.
GBT
+$12.8M
4
PTLA
Portola Pharmaceuticals, Inc.
PTLA
+$11M
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$9.37M

Sector Composition

Rank Sector Weight
1 Healthcare 63.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AVDL
26
DELISTED
Avadel Pharmaceuticals
AVDL
$6.2M 1.25%
+850,000
New +$7.48M
VRAY
27
DELISTED
ViewRay, Inc.
VRAY
$5.79M 1.17%
900,000
– –
ARWR icon
28
Arrowhead Research
ARWR
$10.5B
$5.77M 1.17%
+800,000
New +$4.93M
NGNE icon
29
Neurogene
NGNE
$744M
$5.63M 1.14%
20,000
– –
GTHX
30
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$5.56M 1.12%
+150,000
New +$4M
PTCT icon
31
PTC Therapeutics
PTCT
$6.52B
$5.41M 1.09%
+200,000
New +$5.07M
OBSV
32
DELISTED
ObsEva SA Ordinary Shares
OBSV
$5.4M 1.09%
400,000
-217,100
-35% -$2.66M
NEOS
33
DELISTED
Neos Therapeutics, Inc
NEOS
$4.98M 1.01%
600,000
+300,000
+100% +$2.86M
KDNY
34
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$4.65M 0.94%
+100,000
New +$3.66M
FXF icon
35
Invesco CurrencyShares Swiss Franc Trust
FXF
$420M
$4.51M 0.91%
+45,800
New +$4.55M
MRSN
36
DELISTED
Mersana Therapeutics
MRSN
$4.39M 0.89%
+11,130
New +$4.39M
TGTX icon
37
TG Therapeutics
TGTX
$8.4B
$4.26M 0.86%
+300,000
New +$3.83M
CBIO
38
Crescent Biopharma
CBIO
$407M
$4.06M 0.82%
+2,500
New +$5.2M
LCI
39
DELISTED
Lannett Company, Inc.
LCI
$4.01M 0.81%
+62,500
New +$4.82M
CLVS
40
DELISTED
Clovis Oncology, Inc.
CLVS
$3.96M 0.8%
75,000
-25,000
-25% -$1.46M
INFI
41
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$3.67M 0.74%
+1,750,000
New +$3.75M
TSRO
42
DELISTED
TESARO, Inc.
TSRO
$3.54M 0.72%
+61,900
New +$3.98M
SLDB icon
43
Solid Biosciences
SLDB
$858M
$2.89M 0.58%
+25,667
New +$8.67M
JNCE
44
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$2.8M 0.57%
+125,092
New +$2.78M
DBVT
45
DBV Technologies
DBVT
$870M
$2.31M 0.47%
10,000
-22,500
-69% -$5.32M
BHVN
46
CALL
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$1.94M 0.39%
+75,100
New +$2.25M
SAGE
47
DELISTED
Sage Therapeutics
SAGE
$1.79M 0.36%
11,100
-10,437
-48% -$1.77M
CPRX
48
DELISTED
Catalyst Pharmaceutical
CPRX
$1.31M 0.27%
550,000
– –
KPTI icon
49
Karyopharm Therapeutics
KPTI
$216M
$1.03M 0.21%
+5,119
New +$1.02M
NBRV
50
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$1.01M 0.2%
800
– –
1
2
3 4

Similar funds

SF
Susquehanna Foundation Bala Cynwyd, Pennsylvania $333M AUM 35.73% 1-Year Est. Return
AFS
Annapolis Financial Services Annapolis, Maryland $338M AUM 23.49% 1-Year Est. Return
SFA
Source Financial Advisors New York $338M AUM 33.62% 1-Year Est. Return
E
ETFidea Syracuse, New York $316M AUM 29.57% 1-Year Est. Return
OHCM
Oak Hill Capital Management New York $310M AUM 17.23% 1-Year Est. Return
MC
Minot Capital Broomfield, Colorado $353M AUM 25.25% 1-Year Est. Return
BRA
Biechele Royce Advisors Fishers, Indiana $303M AUM 20.64% 1-Year Est. Return
S
Syntrinsic Denver, Colorado $301M AUM 27.27% 1-Year Est. Return

Ghost Tree Capital's Q1 2018 Portfolio in Review

As of Q1 2018, Ghost Tree Capital held 80 positions worth $494M, up 16% from $426M the previous quarter. Its ten largest holdings account for 53% of the portfolio.

Ghost Tree Capital withdrew a net $71M in Q1 2018, closing 27 positions and reducing 10 holdings. Its most notable exit was Esperion Therapeutics, an estimated $15.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 63% of assets, up from 52% a quarter earlier.

Against the trend, Ghost Tree Capital opened a new position in Sarepta Therapeutics worth $17.4M.

  • Ghost Tree Capital's largest Q1 2018 buy was Sarepta Therapeutics: 235,000 shares worth $17.4M.
  • Ghost Tree Capital added most to Biohaven Pharmaceutical Holding Company Ltd. in Q1 2018, an estimated $10.9M increase.
  • Ghost Tree Capital's biggest Q1 2018 reduction was Mirati Therapeutics, Inc. Common Stock, cutting an estimated $9.37M.
  • Ghost Tree Capital fully exited Esperion Therapeutics in Q1 2018, selling an estimated $15.1M.
  • Ghost Tree Capital's ten largest holdings make up 53% of its $494M portfolio in Q1 2018.
  • Ghost Tree Capital opened 31 new positions and closed 27 in Q1 2018.
  • Ghost Tree Capital's portfolio value rose 16% quarter-over-quarter to $494M.

Based on Ghost Tree Capital's 13F filing for Q1 2018, filed 15 May 2018.